High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression

被引:96
|
作者
Roh, Michael H. [2 ]
Yassin, Yosuf [3 ]
Miron, Alexander [3 ]
Mehra, Karishma K. [1 ,4 ]
Mehrad, Mitra [1 ,4 ]
Monte, Nicolas M. [1 ,4 ]
Mutter, George L. [1 ,4 ]
Nucci, Marisa R. [1 ,4 ]
Ning, Geng [1 ,4 ]
Mckeon, Frank D. [5 ]
Hirsch, Michelle S. [1 ,4 ]
Wa, Xian [1 ,4 ,6 ]
Crum, Christopher P. [1 ,4 ]
机构
[1] Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, Boston, MA 02115 USA
[2] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA
[3] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA
[6] ASTAR, Inst Med Biol, Singapore, Singapore
关键词
ovarian cancer; p16(ink4); p53; PTEN; PAX2; tubal intraepithelial carcinoma; TUBAL INTRAEPITHELIAL CARCINOMA; PELVIC SEROUS CARCINOMA; MUTATIONS; CANCER; PATHWAYS; TUMORS; WOMEN;
D O I
10.1038/modpathol.2010.119
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
High-grade endometrioid and serous carcinomas of the ovary and fallopian tube are responsible for the majority of cancer deaths and comprise a spectrum that includes early or localized (tubal intraepithelial carcinoma) and advanced (invasive or metastatic) disease. We subdivided a series of these tumors into three groups, (1) classic serous, (2) mixed serous and endometrioid and (3) endometrioid carcinomas and determined: (1) the frequencies of coexisting tubal intraepithelial carcinoma, (2) frequency of a dominant ovarian mass suggesting an ovarian origin and (3) immuno-localization of WT-1, p53, PTEN, PAX2 and p16(ink4). All tumors were analyzed for p53 mutations. Thirty six, 25 and 8% of groups 1-3 were associated with tubal intraepithelial carcinoma (P = 0.09) and 34, 45 and 62% predominated in one ovary (P = 0.028), respectively. Differences in frequencies of diffuse p53 immunostaining (85-93%), WT-1 (70-98%) and p16(ink4) positivity (69-75%) were not significant for all groups. Greater than 95% reduction in PAX2 and PTEN occurred in 67-75 and 5-12%, respectively; however, PAX2 and PTEN staining intensity, when present, was often heterogeneous, highlighting different tumor populations. PAX2 and PTEN expression were markedly reduced or absent in 12 of 12 and 4 of 12 tubal intraepithelial carcinomas. In summary, high-grade mullerian carcinomas share identical frequencies of altered or reduced expression of p53, PTEN and PAX2, all of which can be appreciated in tubal intraepithelial carcinomas. Because only a subset of these tumors appears to arise in the fallopian tube, attention to expression of these biomarkers in the ovary and other mullerian sites might facilitate the identification of other carcinogenic pathways. PAX2 and PTEN, in addition to p53 and p16(ink4), comprise a potentially important gene combination in high-grade pelvic carcinogenesis. Modern Pathology (2010) 23, 1316-1324; doi:10.1038/modpathol.2010.119; published online 18 June 2010
引用
收藏
页码:1316 / 1324
页数:9
相关论文
共 50 条
  • [21] bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas
    Diebold, J
    Baretton, G
    Felchner, M
    Meier, W
    Dopfer, K
    Schmidt, M
    Lohrs, U
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1996, 105 (03) : 341 - 349
  • [22] Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma
    Serra, M
    Maurici, D
    Scotlandi, K
    Barbanti-Brodano, G
    Manara, MC
    Benini, S
    Picci, P
    Bertoni, F
    Bacci, G
    Sottili, S
    Baldini, N
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1999, 14 (02) : 301 - 307
  • [23] Inhibition of PAX2 expression results in alternate cell death pathways in prostate cancer cells differing in p53 status
    Gibson, Willietta
    Green, Ashley
    Bullard, Rebecca S.
    Eadd, Andre C.
    Donald, Carlton D.
    CANCER LETTERS, 2007, 248 (02) : 251 - 261
  • [24] Molecular Characterization of an Intact p53 Pathway Subtype in High-Grade Serous Ovarian Cancer
    Hayano, Takahide
    Yokota, Yuki
    Hosomichi, Kazuyoshi
    Nakaoka, Hirofumi
    Yoshihara, Kosuke
    Adachi, Sosuke
    Kashima, Katsunori
    Tsuda, Hitoshi
    Moriya, Takuya
    Tanaka, Kenichi
    Enomoto, Takayuki
    Inoue, Ituro
    PLOS ONE, 2014, 9 (12):
  • [25] Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets
    Chen, Shuhui
    Cavazza, Elisa
    Barlier, Catherine
    Salleron, Julia
    Filhine-Tresarrieu, Pierre
    Gavoilles, Celine
    Merlin, Jean-Louis
    Harle, Alexandre
    ONCOLOGY LETTERS, 2016, 12 (05) : 3264 - 3272
  • [26] p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant
    Hodgson, Anjelica
    Xu, Bin
    Downes, Michelle R.
    HISTOPATHOLOGY, 2017, 71 (02) : 296 - 304
  • [27] Expression of p53 and PTEN in human primary endometrial carcinomas: Clinicopathological and immunohistochemical analysis and study of their concomitant expression
    Stavropoulos, Aggelis
    Varras, Michail
    Vasilakaki, Thivi
    Varra, Viktoria-Konstantina
    Tsavari, Aikaterini
    Varra, Fani-Niki
    Nonni, Aphrodite
    Kavantzas, Nikolaos
    Lazaris, Andreas C.
    ONCOLOGY LETTERS, 2019, 17 (05) : 4575 - 4589
  • [28] MUTATIONS IN THE P53 GENE ARE NOT LIMITED TO CLASSIC HOT-SPOTS AND ARE NOT PREDICTIVE OF P53 PROTEIN EXPRESSION IN HIGH-GRADE NON-HODGKINS-LYMPHOMA
    KOCIALKOWSKI, S
    PEZZELLA, F
    MORRISON, H
    JONES, M
    LAHA, S
    HARRIS, AL
    MASON, DY
    GATTER, KC
    BRITISH JOURNAL OF HAEMATOLOGY, 1995, 89 (01) : 55 - 60
  • [29] Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing
    Cole, Alexander J.
    Dwight, Trisha
    Gill, Anthony J.
    Dickson, Kristie-Ann
    Zhu, Ying
    Clarkson, Adele
    Gard, Gregory B.
    Maidens, Jayne
    Valmadre, Susan
    Clifton-Bligh, Roderick
    Marsh, Deborah J.
    SCIENTIFIC REPORTS, 2016, 6
  • [30] High-Grade and Low-Grade Pelvic Serous Neoplasms Demonstrate Differential p53 Immunoreactivity in Peritoneal Washings
    Chang, Martin C.
    Cibas, Edmund S.
    Crum, Christopher P.
    Kindelberger, David W.
    ACTA CYTOLOGICA, 2011, 55 (01) : 79 - 84